糖尿病アッセイ市場：規模、セグメント別、シェア、法規制、償還、手技、2033年までの予測

糖尿病アッセイは、糖尿病の発症リスクが高い人を診断するために実施されます。糖尿病を診断するために行われる検査には、糖化ヘモグロビン（HbA1c）アッセイ、空腹時グルコースアッセイ、c-ペプチドアッセイ、インスリンアッセイなどがあります。ヘモグロビン（HbA1c）測定は、どの地域でも糖尿病の初回スクリーニングと確認スクリーニングの両方に最も一般的に使用されています。米国糖尿病学会（ADA）は、治療目標を達成している患者には年2回のHbA1c検査を、治療目標を達成していない患者には追加検査を推奨しています。検査結果が正常な患者では、3年ごとにスクリーニングを繰り返すことができます。

糖尿病アッセイは、糖化ヘモグロビン（HbA1c）アッセイ、空腹時血糖アッセイ、糖化ヘモグロビン（HbA1c）ラボアッセイ、糖化ヘモグロビン（HbA1c）POCアッセイ、インスリンアッセイ、C-ペプチドアッセイに区分されます。

当レポートは、世界の糖尿病アッセイ市場について詳細に考察し、市場における競合情勢、SWOT分析、2033年までの市場予測、COVID-19の影響、地域、国別の動向などを提供しています。

目次

現在上市されている糖尿病アッセイと競合情勢

• 主要な業界動向の洞察
• 糖尿病アッセイのセグメント別総市場収益と2015年～2033年の市場展望
• 個数、平均販売価格、市場価値に関する詳細データ

世界、地域、国別の洞察

• 糖尿病アッセイ市場のSWOT分析
• 糖尿病アッセイ市場に関する競合力学の洞察と動向
• 国別の医療制度の概要
• 国別の償還政策
• 国別の医療技術に関する規制の状況

Abstract

Diabetes Assays Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on Diabetes Assays market for the year 2020 and beyond. Diabetes Assays are performed to diagnose individuals at higher risk of developing the disease. Tests that are performed to diagnosis diabetes include glycated haemoglobin (HbA1c) assays, fasting glucose assays, c-peptide assays, and insulin assays. Haemoglobin (HbA1c) assays are the most commonly used for both initial and confirmatory screening of diabetes across all geographical regions. The American Diabetes Association (ADA) recommends HbA1c tests 2 times per year in patients who are meeting treatment goals and additional testing for patients who are not meeting their treatment goals. Screening may be repeated every three years in patients that have normal test results.

Diabetes Assays is segmented into Glycated Hemoglobin Assays (HbA1c), Fasting Glucose Assays, Glycated Hemoglobin (HbA1c) Lab Assay, Glycated Hemoglobin (HbA1c) Point of care (POC) Assay, Insulin Assays, C-Peptide Assays.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed Diabetes Assays tests and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total Diabetes Assays tests market revenue by segment and market outlooks from 2015-2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Diabetes Assays Tests market.
• Competitive dynamics insights and trends provided for Diabetes Assays Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Abbott Laboratories, ALPCO Diagnostics, Bio-Rad Laboratories Inc, DiaSorin SpA, Quidelortho Corp, Sinocare Inc, Danaher Corp, F. Hoffmann-La Roche Ltd, Siemens AG, Tosoh Corp, EKF Diagnostics Holdings Plc, and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for:

• CMO executives who must have deep understanding of the Diabetes Assays market place to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to:

• Understand the impact of COVID-19 on Diabetes Assays market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving Diabetes Assays market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Diabetes Assays market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific Diabetes Assays market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.